Drug news
Baricitinib is filed at FDA to treat rheumatoid arthritis- Eli Lilly + Incyte
Eli Lilly and Company and Incyte Corporation announced that Lilly has submitted a new drug application (NDA) to the FDA for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
Comment: Unlike the injected TNF blockers, baricitinib is orally administered. It is a selective JAK1 and JAK2 inhibitor that spares JAK3.